As of 2024-12-15, the EV/EBITDA ratio of Nektar Therapeutics (NKTR) is -1.14. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NKTR's latest enterprise value is 156.20 mil USD. NKTR's TTM EBITDA according to its financial statements is -136.72 mil USD. Dividing these 2 quantities gives us the above NKTR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.2x - 11.6x | 10.9x |
| Forward P/E multiples | 16.6x - 20.3x | 19.2x |
| Fair Price | (12.17) - (8.41) | (10.99) |
| Upside | -1305.0% - -932.2% | -1188.3% |
| Date | EV/EBITDA |
| 2024-12-13 | -1.14 |
| 2024-12-12 | -1.13 |
| 2024-12-11 | -1.16 |
| 2024-12-10 | -1.16 |
| 2024-12-09 | -1.14 |
| 2024-12-06 | -1.16 |
| 2024-12-05 | -1.16 |
| 2024-12-04 | -1.16 |
| 2024-12-03 | -1.22 |
| 2024-12-02 | -1.37 |
| 2024-11-29 | -1.32 |
| 2024-11-27 | -1.30 |
| 2024-11-26 | -1.22 |
| 2024-11-25 | -1.25 |
| 2024-11-22 | -1.20 |
| 2024-11-21 | -1.14 |
| 2024-11-20 | -1.13 |
| 2024-11-19 | -1.17 |
| 2024-11-18 | -1.17 |
| 2024-11-15 | -1.22 |
| 2024-11-14 | -1.36 |
| 2024-11-13 | -1.51 |
| 2024-11-12 | -1.55 |
| 2024-11-11 | -1.63 |
| 2024-11-08 | -1.67 |
| 2024-11-07 | -1.63 |
| 2024-11-06 | -1.66 |
| 2024-11-05 | -1.67 |
| 2024-11-04 | -1.57 |
| 2024-11-01 | -1.44 |
| 2024-10-31 | -1.39 |
| 2024-10-30 | -1.47 |
| 2024-10-29 | -1.49 |
| 2024-10-28 | -1.61 |
| 2024-10-25 | -1.56 |
| 2024-10-24 | -1.60 |
| 2024-10-23 | -1.68 |
| 2024-10-22 | -1.72 |
| 2024-10-21 | -1.66 |
| 2024-10-18 | -1.68 |
| 2024-10-17 | -1.74 |
| 2024-10-16 | -1.64 |
| 2024-10-15 | -1.52 |
| 2024-10-14 | -1.56 |
| 2024-10-11 | -1.61 |
| 2024-10-10 | -1.52 |
| 2024-10-09 | -1.53 |
| 2024-10-08 | -1.53 |
| 2024-10-07 | -1.51 |
| 2024-10-04 | -1.56 |